Augma Biomaterials

Company Overview

Snapshot

Founded in November 2009, Augma Biomaterials operates with 11–50 employees. The company specializes in developing synthetic bone substitutes for the dental market, with its 3D Bond and Bond Apatite products being FDA cleared and CE approved. In January 2019, the inventor of its bone-regrowing dental material technology was recognized as an Edison Awards Finalist.

Business overview

Augma Biomaterials is a Health Tech & Life Sciences company focused on the development, production, and marketing of synthetic bone substitutes for the dental market. Its core products, 3D Bond and Bond Apatite, are biomaterials designed to function as scaffolds for bone regeneration in dental procedures, filling, augmenting, or reconstructing bony defects in the oral and maxillofacial regions. The company serves the healthcare industry, particularly dentists and clinics, with solutions for medical technologies, surgery, and regenerative medicine.

Strategic signal

In January 2019, the inventor behind Augma Biomaterials' dental material technology, which facilitates bone regrowth, was named an Edison Awards Finalist. This recognition highlights the innovative nature and potential impact of the company's biomaterial solutions within the dental and regenerative medicine sectors, signaling strong validation for its core technology and product development capabilities.

Company Intelligence Q&A

What is Augma Biomaterials' primary focus?

Augma Biomaterials is dedicated to the development, production, and marketing of synthetic bone substitutes specifically for the dental market.

What are Augma Biomaterials' key products?

The company's key products include 3D Bond, a biphasic calcium sulfate functioning as a scaffold for bone regeneration, and Bond Apatite, which combines 3D Bond with hydroxyapatite granules to create a cement-based osteoconductive composite.

What regulatory approvals have Augma Biomaterials' products received?

Augma Biomaterials' Bond Apatite product is FDA cleared and CE approved, indicating compliance with significant health and safety standards for medical devices.

In which markets does Augma Biomaterials operate?

Augma Biomaterials operates in various global markets, including Germany, the United Kingdom, Israel, France, Romania, South Africa, Hungary, Sweden, Turkey, Poland, and the United States.

What recognition did Augma Biomaterials receive in January 2019?

In January 2019, the inventor of Augma Biomaterials' dental material technology, which enables bone regrowth, was recognized as an Edison Awards Finalist.